Survodutide
Also known as: BI 456906
A glucagon/GLP-1 dual agonist in development for MASH and obesity.
Overview
Survodutide is a dual glucagon and GLP-1 receptor agonist being developed by Boehringer Ingelheim, primarily targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
Mechanism of Action
Combines GLP-1 appetite suppression with glucagon-mediated hepatic effects. The glucagon component promotes hepatic lipid oxidation and energy expenditure while GLP-1 provides metabolic and weight benefits.
Pharmacokinetics
Weekly subcutaneous dosing with sustained activity.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
1
Titration
Dose
0.5-4.8 mg
Frequency
Once weekly
Duration
Variable
Dose escalation protocol
Research Areas
MASH/NASHObesityType 2 DiabetesLiver Disease
Key Research Findings
- 1Phase 2 MASH trials showed significant liver fat reduction and fibrosis improvement
- 2Weight loss of up to 19% in obesity trials
- 3Histological improvement in liver biopsies
- 4Advancing to Phase 3 for MASH indication
Side Effects & Contraindications
Reported Side Effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
Contraindications
- Pregnancy
- Decompensated liver disease
Safety Considerations
GI side effects common. Monitoring hepatic function recommended.
Storage Requirements
Refrigerate at 2-8C
Scientific References
- 1
Quick Reference
Category
Weight Loss & MetabolicSequence
Proprietary dual agonist sequence
Molecular Weight
~4500 g/mol
Half-Life
~5-6 days
Bioavailability
High (SC)
Research Stage
clinical phase 3
Administration
Subcutaneous injection (weekly)